A review of autologous stem cell transplantation in lymphoma
Current hematologic malignancy reports, 2017•Springer
Abstract Purpose of Review Chemotherapy remains the first-line therapy for aggressive
lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15%
with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-
dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.
Recent Findings There is some utility of upfront consolidation for-high risk/high-grade B-cell
lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar …
lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15%
with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-
dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.
Recent Findings There is some utility of upfront consolidation for-high risk/high-grade B-cell
lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar …
Purpose of Review
Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20–30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients.
Recent Findings
There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL. New conditioning regimens are being investigated which have demonstrated an improved safety profile without compromising the myeloablative efficiency for relapsed or refractory HL.
Summary
Salvage chemotherapy followed by HDT and rescue autologous stem cell transplant remains the standard of care for relapsed/refractory lymphoma. The role of novel agents to improve disease-related parameters remains to be elucidated in frontline induction, disease salvage, and high-dose consolidation or in the maintenance setting.
Springer